Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Samuel S. Herrod"'
Publikováno v:
Multiple Sclerosis and Related Disorders. 30:176-186
Oral cladribine is a novel treatment for relapsing multiple sclerosis (MS). This appears to be a semi-selective immune-reconstitution therapy that induces long-term therapy from short treatment cycles. It has a relatively good safety profile that cur
Publikováno v:
JAMA neurology. 74(8)
Importance Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits relapsing multiple sclerosis (MS) but is associated with a high incidence of secondary B-cell autoimmunities that limit use. These effects may be avoided through contr
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 88:A52.1-A52
Background The use of alemtuzumab in people with relapsing MS (pwRMS) is limited by the high risk of secondary B cell autoimmunity (SAI). Data describing the effect of alemtuzumab on lymphocyte subsets collected during the phase III trials has never
Autor:
Lukasz Zalewski, Klaus Schmierer, David Baker, Christo Albor, Samuel S. Herrod, Cesar Alvarez-Gonzalez
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
Objective:To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies.Methods:The regulatory sub